EBR Systems

Executive Summary

EBR Systems is a medical device company pioneering the WiSE System, the world's only leadless left ventricular endocardial pacing (LVEP) device for cardiac resynchronization therapy (CRT). Founded in 2003 and headquartered in Sunnyvale, California, the company addresses a critical unmet need in heart failure treatment. Conventional CRT relies on a coronary sinus lead, which can be difficult to place and is associated with high failure rates. The WiSE System eliminates the need for this lead by delivering pacing energy directly to the left ventricle via a miniaturized electrode, enabling more physiologic pacing and potentially improving outcomes for patients who are non-responders or not candidates for standard CRT. With over two decades of development, EBR Systems is positioned to disrupt the $4 billion CRT market.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of the WiSE System70% success
• Q3 2026Publication of SOLVE-CRT pivotal trial results85% success
• H1 2026Strategic partnership or licensing deal with major cardiovascular company60% success